Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.727 EUR
−293.53 M EUR
212.04 M EUR
95.25 M
About REVANCE THERAPEUT.DL-,001
Sector
CEO
Mark J. Foley
Headquarters
Nashville
Website
Founded
1999
FIGI
BBG005ZVC4J9
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
RVNC5133129
Revance Therapeutics, Inc. 1.75% 15-FEB-2027Yield to maturity
1.88%
Maturity date
Feb 15, 2027
Explore more bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BER exchange REVANCE THERAPEUT.DL-,001 stocks are traded under the ticker RTI.
We've gathered analysts' opinions on REVANCE THERAPEUT.DL-,001 future price: according to them, RTI price has a max estimate of 6.36 EUR and a min estimate of 6.36 EUR. Watch RTI chart and read a more detailed REVANCE THERAPEUT.DL-,001 stock forecast: see what analysts think of REVANCE THERAPEUT.DL-,001 and suggest that you do with its stocks.
Yes, you can track REVANCE THERAPEUT.DL-,001 financials in yearly and quarterly reports right on TradingView.
REVANCE THERAPEUT.DL-,001 is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
RTI earnings for the last quarter are −0.33 EUR per share, whereas the estimation was −0.24 EUR resulting in a −37.54% surprise. The estimated earnings for the next quarter are −0.33 EUR per share. See more details about REVANCE THERAPEUT.DL-,001 earnings.
REVANCE THERAPEUT.DL-,001 revenue for the last quarter amounts to 53.78 M EUR, despite the estimated figure of 61.23 M EUR. In the next quarter, revenue is expected to reach 65.48 M EUR.
RTI net income for the last quarter is −34.23 M EUR, while the quarter before that showed −34.98 M EUR of net income which accounts for 2.15% change. Track more REVANCE THERAPEUT.DL-,001 financial stats to get the full picture.
No, RTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 9, 2025, the company has 597.00 employees. See our rating of the largest employees — is REVANCE THERAPEUT.DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REVANCE THERAPEUT.DL-,001 EBITDA is −143.64 M EUR, and current EBITDA margin is −88.46%. See more stats in REVANCE THERAPEUT.DL-,001 financial statements.
Like other stocks, RTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REVANCE THERAPEUT.DL-,001 stock right from TradingView charts — choose your broker and connect to your account.